1. Abiraterona and arn-509 acetic acid pharmaceutical formula can be used for the management of mammals, especially humans, suffering from diseases or diseases related to male receptor (AR)；Especially cancer, especially prostate cancer, including but not limited to: prostate cancer without castration, prostate cancer without castration, prostate cancer without castration for patients without chemotherapy, Non metabolic prostate cancer that is sensitive to biochemical compound hormones or resistant to high-risk castration. On one hand, these formulations include solid dispersion of ammonium nitrite acetic acid and rna-509, and polymers selected between hpmcas, acrylic copolymers and their mixtures. In one aspectThese formulations include a particle of ammonium nitrite acetate and a solid dispersion of rna-509, as well as a polymer selected between hpmcas, acrylic copolymers and their mixtures. 13. Claim 13: the process of formulating the pharmaceutical formulation of claim 1, including (a) preparing the solid dispersion of rn-509 and selected polymer between hpmcas or acrylic copolymer (MET) and making a mixture； (b) preparing a particle containing ammonium nitrite and acetic acid； (c) Mix the solid dispersion of (a) and (b) particles with a vehicle that is medically acceptable. Requirement 20: combination,It includes pharmaceutical preparations that meet any requirements and glucose selected from the population, including prednisone, prednisone, methylprednisone, glucose, and pharmaceutically acceptable salts and acetic acid.Formulaciones farmacéuticas de acetato de abiraterona y ARN-509, que se pueden administrar a mamíferos, en particular a humanos, que sufren de una enfermedad o afección relacionada con un receptor androgénico (AR), en particular, cáncer, más particularmente, cáncer de próstata, que incluye entre otros, cáncer de próstata resistente a la castración, cáncer de próstata metastásico resistente a la castración, cáncer de próstata metastásico resist
